Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and Simcere Pharmaceutical Group have entered into a strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.
Subscribe to our email newsletter
As per the terms of the agreement, Simcere receives exclusive rights to develop and commercialise BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets.
The parties will together determine the strategic development plan, which will initially be performed by Simcere.
Bristol-Myers Squibb Research senior vice president Francis Cuss said that they are excited to embark on this partnership with Simcere.
"Working together we are building on the strengths of both organisations to develop potential medicines and help patients," Cuss said.